– USA, CA – Kyverna Therapeutics, a cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the appointment of Dr. Peter Maag (Ph.D.) to its Board of Directors as CEO, succeeding Dr. Dominic Borie who has stepped to the role of president of research and development.
“We are thrilled to welcome Peter as Kyverna’s new CEO,” said Ian Clark, chair of Kyverna’s board of directors. “Peter is an accomplished executive with extensive industry experience at private and public companies spanning three continents. His consistent record of driving transformational growth in healthcare through product innovation, creative business development, sequential financings, and sound investment strategies will be invaluable to progress Kyverna and deliver on its mission to help bring new and much-needed treatment options to patients with serious autoimmune and inflammatory diseases.”
About Dr. Peter K. Maag
Dr. Maag has over 20 years of executive management experience in the pharmaceutical and diagnostic industry. Most recently, he was executive chairman, president and CEO of CareDx where he had built the company from a small start-up into a public company and industry-leading powerhouse in transplantation through a series of BD&L and financing transactions. CareDx serves the transplant community with breakthrough technologies in more than 60 countries and has created a strong presence in this specialty market. Prior to joining CareDx in 2012, Peter held multiple positions in Novartis with increasing responsibilities. As President of Novartis Diagnostics, he drove growth and innovation in its blood-screening business. Previously, he led one of Novartis’ key affiliates as country president, Germany, and lived in a dynamically growing market as country president, of Korea. At headquarters in Switzerland, he served as the head of the strategy for Novartis Pharmaceuticals and helped launch the Infectious Diseases franchise.
“I am passionate about patient care and am honored to be appointed to lead Kyverna and this extraordinarily talented team. This is such an exciting time to join the company with key milestones like our submission of an IND for our lead candidate, KYV-101 in lupus nephritis tomorrow. This important regulatory milestone will provide a runway to move KYV-101 into the clinical phase and brings us a step closer to developing a new treatment option for lupus nephritis,” said Dr. Peter Maag. “I believe that Kyverna is at the forefront of revolutionizing how we treat severe immune-related and inflammatory diseases with its new class of cell therapies. With multiple shots on goal, I believe that Kyverna is well positioned to transform how autoimmune diseases are treated.”
Prior to joining Novartis, Peter worked at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. Besides supporting various healthcare and tech companies in their growth efforts, he holds board and advisory positions at Phoenix Pharma SE, CareDx, MiroMatrix, and the Personalized Medicine Coalition. Peter studied pharmaceutical sciences in Heidelberg, London, and Berlin.
About Kyverna Therapeutics
Kyverna Therapeutics is a cell therapy company with the mission of engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. In addition to aiming to develop next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic settings, Kyverna is creating synReg T cells, a synthetic version of Regulatory T cells (Tregs), powerful natural immune cells that control immune homeostasis through multiple immunosuppressive mechanisms. By offering more than one mechanism for taming autoimmunity, Kyverna is positioned to act on its mission of transforming how autoimmune diseases are treated.
For more information: https://kyvernatx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.